Cozaar, Atacand Labels Include Class Rhabdomyolysis Risk
Executive Summary
Labeling for Merck's Cozaar (losartan) and AstraZeneca's Atacand (candesartan) includes language describing a class risk for rhabdomyolysis among angiotensin II receptor blockers